Construction and expression of recombinant human AFP eukaryotic expression vector

Li-Wang Zhang, Jun Ren, Liang Zhang, Hong-Mei Zhang, Bin Jin, Bo-Rong Pan, Xiao-Ming Si, Yan-Jun Zhang, Zhong-Hua Wang, Yang-Lin Pan, Stephen M Festein

AIM: To construct a recombinant human AFP eukaryotic expression vector for the purpose of gene therapy and target therapy of hepatocellular carcinoma (HCC).

METHODS: The full length AFP-cDNA of prokaryotic vector was digested, and subcloned to the multi-clony sites of the eukaryotic vector. The constructed vector was confirmed by enzymes digestion and electrophoresis, and the product expressed was detected by electrochemiluminescence and immunofluorescence methods.

RESULTS: The full length AFP-cDNA successfully cloned to the eukaryotic vector through electrophoresis, 0.9723 IU/ml AFP antigen was detected in the supernatant of AFP-CHO by electrochemiluminescence method. Compared with the control groups, the differences were significant (P<0.05). AFP antigen molecule was observed in the plasma of AFP-CHO by immunofluorescence staining.

CONCLUSION: The recombinant human AFP eukaryotic expression vector can express in CHO cell line. It provides experimental data for gene therapy and target therapy of hepatocellular carcinoma.

INTRODUCTION

Hepatocellular carcinoma (HCC) is a very common malignancy in China[1-5], and it has a very poor prognosis[6-9]. Only a minority of patients are eligible for surgical therapies due to advanced tumors or extrahepatic diseases at primary diagnosis[10,11]. Therefore, it is urgent to find a novel strategy to prevent the proliferation of malignant cells. It is a hot spot at present to study prophylactic vaccination targeting the tumor-associated antigen (TAA) or tumor-specific antigen (TSA). This approach has been successful in some model systems, such as the tyrosinase-related protein (TRP)-2 in murine melanoma[12,13]. A colon cancer specific DNA vaccination directed against the carcinoembryonic antigen (CEA) is in phase I clinical trial[14].

The oncofetal alpha-fetoprotein (AFP) may be a possible target for an HCC-specific vaccination. It is a 70-ku to 80-ku secretory protein that is heterogeneously glycosylated. AFP is usually expressed at high concentrations in fetal liver, gastrointestinal tract, and the yolk sack. It is transcriptionally down-regulated after birth, and frequently re-expressed in HCC and therefore, used as a diagnostic marker for this tumor[15-21]. Serum AFP is useful not only for diagnosis, but also a prognostic indicator for HCC patients[22,23]. AFP mRNA has been proposed as a predictive marker of HCC cells disseminated into the circulation and for metastatic recurrence[24-27]. Some experiments in vitro have also demonstrated that AFP promotes cell proliferation of hepatoma cell lines[28,29].

AFP may be used as a target molecule for immunotherapy or prophylaxis against HCC. For this purpose, we constructed the recombinant human AFP eukaryotic expression vector, and hope that it will provide experimental data for the treatment of HCC.

MATERIALS AND METHODS

Cell line and culture condition

CHO cell line was provided by the Department of Biochemistry, Fourth Military Medical University. Cells were maintained in RPMI 1640 medium, supplemented with 10 mL/L FCS, 1 mmol/L glutamine, and 100 kU/L penicillin.

Plasmids

The prokaryotic expression vector pRESTA-AFP containing human full-length AFP-cDNA was presented by Dr. Stephen M Festein, Hamilton College, USA. The eukaryotic vector pCEFL was provided by Dr. Pan YL, Fourth Military Medical University.

Amplification of pRESTA-AFP

Transformation of competent bacterial DH5-α was carried out with pRESTA-AFP. The transformed cell DH5-α was transferred onto LB medium which was anti-aminobenzyl penicillin, cultured overnight in an incubator at 37 °C. Four clones were selected and maintained in LB medium, and shaken overnight at 37 °C.

Evaluation of pRESTA-AFP

Five mL bacterial medium was picked up, and the plasmid...
DNA was extracted following the procedures of EZNA plasmid miniprep kit (Omega). The extracted DNA was digested by BamH I and EcoR I (TaKaRa). The digested products were evaluated with 10 g/L agarose gel electrophoresis.

**Construction of recombinant human AFP eukaryotic expression vector**

The human full-length AFP-cDNA was retrieved following the procedures of UNIQ-10 centrifugation column type gel retrieve kit (Sangon, Shanghai) and ligated to the multi-clony sites of pCEFL that was digested by BamH I and EcoR I at a ratio of 10:1 with T4 DNA ligase (TaKaRa). Amplification, extraction, digestion and evaluation were performed according to the above-mentioned methods. It demonstrated that the full-length AFP-cDNA was inserted into pCEFL successfully, and named pCEFL-AFP.

**Transfections of CHO cells**

CHO cells were transiently transfected with pCEFL-AFP by liposome, Lipofectamine™2000 (Gibco). All the procedures were performed according to the guidance of the reagent. CHO cells were also transfected with pCEFL as control group, CHO cells not being transfected also served as control.

**Detection of AFP expression by electrochemiluminescence**

The supernatants of the cells from the three groups were collected, and detected by electrochemiluminescence method with Elecsys 1010 (Roche) and AFP electrochemiluminescence detection kit (Roche).

**Detection of AFP expression by immunofluorescence**

The transfected cells were stabilized with 10 g/L formaldehyde polymerisatum for 30 minutes at 4 °C, and blocked with 100 g/L bovine serum albumin (BSA) for 1 hour at room temperature, then coated with rabbit anti-human AFP antibody (Dako) for 45 minutes at 37 °C, followed by goat anti-rabbit IgG-FITC (Boster, Wuhan) for 30 minutes at 37 °C. The antibody-coated cells were observed under fluorescence microscope (Optiphot XIF, Nicon, Japan) within 24 hours.

**Statistical analysis**

Student’s t test was used to compare the difference of AFP molecule in the supernatants between control groups and transfected pCEFL-AFP group. P value less than 0.05 was considered statistically significant.

**RESULTS**

**Evaluation of pRESTA-AFP**

pRESTA-AFP was digested by BamH I and EcoR I and evaluated with electrophoresis. Figure 1 shows that pRESTA-AFP contained the full-length human AFP-cDNA.

**Evaluation of pCEFL-AFP**

To demonstrate that the full-length human ACP-cDNA was inserted into the multi-clony sites of pCEFL correctly, pCEFL-AFP was digested by BamH I and EcoR I and evaluated with electrophoresis. Figure 2 shows that ACP-cDNA was inserted into pCEFL successfully.

**Figure 1** Electrophoresis of pRESTA-AFP. 1. Marker, 2. Full length ACP-cDNA in the upper, pRESTA in the lower.

**Figure 2** Electrophoresis of pCEFL-AFP. 1. Marker, 2. Full length ACP-cDNA in the upper, pCEFL in the lower.

**Figure 3** CHO transfected with pCEFL-AFP. The fluorescence staining in the cytoplasm was positive. ×400.

**Figure 4** CHO transfected with pCEFL. The fluorescence staining in the cytoplasm was negative. ×400.

**Figure 5** Non-transfected CHO. The fluorescence staining in the cytoplasm was negative. ×400.
AFP molecule expression in the supernatant
CHO cells were transfected with pCEFL-AFP. To demonstrate that the transfection was successful, the supernatant of CHO cells was detected by electrochemiluminescence method. The results showed that AFP molecule expression in the supernatant of CHO cells transfected with pCEFL-AFP was higher (972.3±69.9 IU/L) than that transfected with pCEFL (556.2±60.2 IU/L, P<0.05) and also higher than that not being transfected (582.3±58.0 IU/L, P<0.05). The differences were significant.

Immunofluorescence staining of transfected cells
The transfected cells were coated with AFP antibody and fluorescent antibody. Under fluorescence microscope, it could be observed that the fluorescence staining was positive in the cytoplasm of CHO cells transfected with pCEFL-AFP and negative in the controls (Figures 3-5).

DISCUSSION
In China, the incidence of HCC is very high, and surgical operation, chemotherapy, and interventional therapy are the common therapies. But only a few patients of earlier stage without extrahepatic malignancy are indicated for operation, and for the advanced cases, chemotherapy and interventional therapy usually cannot achieve a satisfactory effect. AFP is a TAA of HCC, which may be used as a target for treatment.

Vollmer et al[30] firstly showed a prophylactic effect of an AFP-specific DNA vaccination on the growth of AFP-positive tumor cells in C57BL/6 mice. In their experiments, only 7.4 % of mice were fully protected from tumor growth. In the remaining animals, a prolonged time until tumors reached diameters of 10 mm was observed. Wang et al[31] found that antisense S-ODNs targeting AFP gene treatment led to reduced AFP gene expression. Specific antisense S-ODNs, but not control S-ODNs, inhibited the growth of hepatoma cells in vitro. In vitro, only antisense S-ODNs exhibited obvious antitumor activities. Guo et al[32] found that the dendritic cells (DCs) based vaccine with HLA-A2 restricted peptide epitope derived from hAFP have marked cytotoxicity against AFP positive primary HCC. In their experiments, after stimulated by DCs loaded with CTL epitope based peptide derived from hAFP, lymphocytes showed good characteristics and the culture medium of activated lymphocytes contained a high level of Th1 type cytokines of IL-12 and TNF. Activated lymphocytes not only specifically lysed HLA-A2 (+) HepG2 line but also had the cytotoxicity against T2 target cells loaded with peptide of hAFP. Hanke et al[33] demonstrated that DNA vaccination with AFP-encoding plasmid DNA could prevent the growth of subcutaneous AFP-expressing tumors and not interfere with liver regeneration in mice. Grimm et al[34] achieved similar outcomes.

Since immunotherapy or gene therapy targeting TAA or TSA is a direction of tumor therapy, AFP as a TAA of HCC, has shown its profound effect on HCC treatment in animal models. In our experiment, we constructed the recombinant human AFP eukaryotic expression vector successfully. This, we believe, provides experimental data for gene therapy and immunotherapy of HCC. It may be used as a treatment target of human HCC.

REFERENCES
1. Wu W, Lin XB, Qian JM, Ji ZL, Jiang Z. Ultrasonic aspiration hepatectomy. For 136 patients with hepatocellular carcinoma. World J Gastroenterol 2002; 8: 763-765
2. Jiang HC, Liu LX, Piao DX, Xu J, Zheng M, Zhu AL, Qi SY, Zhang WH, Wu LF. Clinical short-term results of radiofrequency ablation in liver cancers. World J Gastroenterol 2002; 8: 624-630
3. Zhang G, Long M, Wu ZZ, Yu WQ. Mechanical properties of hepatocellular carcinoma cells. World J Gastroenterol 2002; 8: 243-246
4. Tang ZY. Hepatocellular carcinoma-source, cause, treatment and metastasis. World J Gastroenterol 2003; 7: 495-498
5. Ren C, Pilz T, Klosserman C, Berna M, Schild HH, Sauerbruch T, Caselmann WH. Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma. World J Gastroenterol 2001; 7: 208-215
6. Jiang YF, Yang ZH, Hu JQ. Recurrence or metastasis of HCC: predictors, early detection and experimental antiangiogenic therapy. World J Gastroenterol 2000; 6: 61-65
7. Zhao WH, Ma ZM, Zhou XR, Feng YZ, Fang BS. Prediction of recurrence and prognosis in patients with hepatocellular carcinoma after resection by use of CLIP score. World J Gastroenterol 2002; 8: 237-242
8. Qin LX, Tang ZY. The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol 2002; 8: 385-392
9. Zeng WJ, Liu GY, Xu J, Zhou XD, Zhang YE, Zhang N. Pathological characteristics, PCNA labeling index and DNA index in prognostic evaluation of patients with moderately differentiated hepatocellular carcinoma. World J Gastroenterol 2002; 8: 1040-1044
10. Durr R, Caselmann WH. Carcinogenesis of primary liver malignancies. Langenbecks Arch Surg 2000; 385: 154-161
11. Caselmann WH, Blume HM, Fleig WE, Huppert PE, Ramadori G, Schirmer C, Sauerbruch T. Guidelines of the german society of digestive and metabolic diseases for diagnosis and therapy of hepatocellular carcinoma. German society of digestive and metabolic diseases. Z Gastroenterol 1999; 37: 353-365
12. Bronte V, Apolloni E, Ronca R, Zamboni P, Overwijk WW, Surman DR, Redifo N, Zanovello P. Genetic vaccination with ”self” tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res 2000; 60: 253-258
13. Tuting V, Gambotto A, DeLeo A, Lotze MT, Robbins PD, Storkus WJ. Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Ther 1999; 6: 73-80
14. Conry RM, LoBuglio AF, Lochech F, Moore SE, Sumerel LA, Barlow DL, Pike J, Curiel DT. A carcinomaembryonic antigen polynucleotide vaccine for human clinical use. Cancer Gene Ther 1999; 2: 33-38
15. Shen LJ, Zhang ZJ, Ou YM, Zhang HX, Huang R, He Y, Wang MJ, Xu GS. Computed morphometric analysis and expression of alpha-fetoprotein in hepatocellular carcinoma and its related lesion. World J Gastroenterol 2000; 6: 415-416
16. Dhib-Junnsupwan P, Piratsivuth T, Tanomkiet W, Apakupakul N, Yongvo S. Review of 336 patients with hepatocellular carcinoma at Songklanagarind Hospital. World J Gastroenterol 2000; 6: 393-349
17. Wawrzynowicz-Syczewska M, Leoncik A, Jurczyk K, Karpinska E, Boron-Kaczmarska A. Increased incidence of hepatocellular carcinoma. Pol Merkuriusz Lek 2002; 13: 100-102
18. Chou SF, Hsu WL, Hwang JM, Chen CY. Production of monoclonal and polyclonal antibodies against human alpha-fetoprotein, a hepatocellular tumor marker, Hybrid Hybridomics 2002; 21: 301-305
19. Chu PG, Ishizawa S, Wu E, Weiss LM. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein. Am J Surg Pathol 2002; 26: 978-988
20. Nguyen MH, Garcia RT, Simpson PW, Wright TL, Keeffe EB. Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology 2002; 36: 410-417
21. Maj G, Gong Q, Lin M. Combined five tumor markers in detecting primary hepatic carcinoma. Zhonghua Wai Ke Za Zhi 2002; 38: 14-16
22. Qin LX, Tang ZY. The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol 2002; 8: 193-199
23. Song BC, Suh DJ, Yang SH, Lee HC, Chung YH, Sung KB, Lee YS. Lens culinaris agglutinin-reactive alpha-fetoprotein as a prognostic marker in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization. J Clin Gastroenterol 2002; 35: 398-402
24 Witzigmann H, Geissler F, Benedix F, Thiery J, Uhlimann D, Tannapfel A, Wittekind C, Hauss J. Prospective evaluation of circulating hepatocytes by alpha-fetoprotein messenger RNA in patients with hepatocellular carcinoma. Surgery 2002; 131: 34-43

25 Ijichi M, Takayama T, Matsumura M, Shiratori Y, Omata M, Makuuchi M. Alpha-Fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: a prospective study. Hepatology 2002; 35: 853-860

26 Wu X, Lin Z, Fan J, Liu J, Wang L, Tang Z. Quantitation of alpha-fetoprotein messenger RNA in peripheral blood of nude mice and its relationship with tumor recurrence and metastasis after curative resection of hepatocellular carcinoma. Zhonghua Ganzangbing Zazhi 2002; 10: 189-191

27 He P, Tang ZY, Ye SL, Liu BB. Relationship between expression of alpha-fetoprotein messenger RNA and some clinical parameters of human hepatocellular carcinoma. World J Gastroenterol 1999; 5: 111-115

28 Li MS, Li PF, He SP, Du GG, Li G. The promoting molecular mechanism of alpha-fetoprotein on the growth of human hepatoma Bel-7402 cell line. World J Gastroenterol 2002; 8: 469-475

29 Li MS, Li PF, Li G, Du GG. Enhancement of Proliferation of HeLa Cells by the alpha-Fetoprotein. Shengwu Huaxue Yu Shengwu Wuli Xuebao 2002; 34: 769-774

30 Vollmer CM Jr, Eliber FC, Butterfield LH, Ribas A, Dissette VB, Koh A, Montego LD, Lee MC, Andrews KJ, McBride WH, Glaspy JA, Economou JS. Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res 1999; 59: 3064-3069

31 Wang XW, Yuan JH, Zhang RG, Guo LX, Xie Y, Xie H. Antihepatoma effect of alpha-fetoprotein antisense phosphorothioate oligodeoxynucleotides in vitro and in mice. World J Gastroenterol 2001; 7: 345-351

32 Guo J, Cai M, Wei D, Qin L, Huang J, Wang X. Immune responses of dendritic cells after loaded with cytotoxicity T lymphocyte epitope based peptide of human alpha-fetoprotein (hAFP). Zhonghua Ganzangbing Zazhi 2002; 10: 178-180

33 Hanke P, Serve M, Dombrowski F, Sauerbruch T, Caselmann WH. DNA vaccination with AFP-encoding plasmid DNA prevents growth of subcutaneous AFP-expressing tumors and does not interfere with liver regeneration in mice. Cancer Gene Ther 2002; 9: 346-355

34 Grimm CF, Ortmann D, Michalak S, Krohne TU, Meckel S, Eisele E, Encke J, Blum HE, Geissler M. Mouse alpha-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice. Gastroenterology 2000; 119: 1104-1112

Edited by Ma JY